Presence of PsA increases prevalence of anxiety and depression in psoriasisJuly 31, 2022Psoriatic Arthritis
PsA: Clinical and therapeutic features associated with early vs late onset of psoriasisJuly 31, 2022Psoriatic Arthritis
Reluctance of biologic initiation in systemic-therapy-naive PsA patients receiving apremilastJuly 31, 2022Psoriatic Arthritis
PsA: Long-term retention, efficacy, and safety of secukinumab in real worldJuly 31, 2022Psoriatic Arthritis
Guselkumab leads to meaningful and consistent improvement in general health outcomes in PsAJuly 31, 2022Psoriatic Arthritis
PsA: Risankizumab improves patient-reported outcomes in phase 3 trialJuly 31, 2022Psoriatic Arthritis
PsA: Sustained improvement in patient-reported outcomes with bimekizumabJuly 31, 2022Psoriatic Arthritis
PsA: Long-term efficacy and safety of ixekizumab with or without csDMARDJuly 31, 2022Psoriatic Arthritis
Rapid and sustained improvement in diverse PsA manifestations with guselkumabJuly 31, 2022Psoriatic Arthritis
Questionnaire for patients with psoriasis might identify risk of axial involvementJuly 26, 2022Psoriatic Arthritis
NAFLD strongly correlated with psoriasis, PsA; risk linked to severityJuly 20, 2022Psoriatic Arthritis
New algorithm for initial PsA treatment choice is driven by T-cell behaviorJuly 18, 2022Psoriatic Arthritis
